Roth J, Růzicka E, Mecír P
Neurologická klinika 1. LF UK a VFN Praha.
Cas Lek Cesk. 1994 Nov 7;133(21):665-7.
The reactivity of postsynaptic dopamine receptors in the striatum is preserved in Parkinson's disease (PD) but not in parkinsonian syndromes of various origin (PS). Hence, the effect of dopaminergic stimulation can serve as one of the diagnostic criteria allowing to distinguish between PD and PS. The present study aimed to ascertain the clinical utility of Apomorphine (APO), a powerful short acting direct D1 and D2 receptors agonist drug, in the differential diagnosis of PD and PS.
We studied 39 patients presenting parkinsonian signs. Based on clinical examination, 23 subjects (7 f, 16 m, mean age (SD) 59.2 (7.8) years were diagnosed as having probable PD, and 16 patients (5 f, 11 m, mean age 72 (7.6) yrs, p < 0.001) as having probable PS. In the PD group, mean Hoehn and Yahr degree of severity was 2.7 (1.1), mean duration of the disease 9.5 (6.2) yrs, mean duration of L-DOPA treatment (20 patients) 6.7 (5.5) yrs. In the PS group, the respective values of Hoehn and Yahr were 3.3 (0.9), mean duration of the disease 6.2 (4.1) yrs and mean duration of L-DOPA treatment (10 patients) 1.6 (1.1) yrs. After an overnight withdrawal of all other dopaminergic medication, a single subcutaneous dose of Apomorphine hydrochloride solution corresponding to 0.05 mg per kg of weight was administered. Domperidone was given 60 mg daily prior to the testing to avoid undesirable peripheral effects of APO. 20 minutes after APO administration, we noted a marked clinical improvement i.e. at least 30% decrease of pre-treatment motor score values on Columbina University Rating Scale (CURS) in 19 of 23 PD and in one of 16 PS patients. In the PD group, the difference between mean CURS values, 30.7 (19.5) before and 14.7 (10.3) after APO was highly significant (p < 0.001). In the PS group, only a slight posttreatment CURS decrease was found, 39.8 (17.5) before and 37.8 (17.5) after APO (p < 0.05).
In individual patients, these results mostly confirm the presumed diagnosis of PD or PS. Even in the most serious cases from the PD group, the testing showed that the function of dopamine receptors in the striatum was still preserved. Thus, the Apomorphine test appears to be a helpful tool for differential diagnosis of PD and PS.
纹状体中突触后多巴胺受体的反应性在帕金森病(PD)中得以保留,但在各种病因的帕金森综合征(PS)中则不然。因此,多巴胺能刺激的效果可作为区分PD和PS的诊断标准之一。本研究旨在确定阿扑吗啡(APO),一种强效短效的直接D1和D2受体激动剂药物,在PD和PS鉴别诊断中的临床效用。
我们研究了39例出现帕金森症状的患者。基于临床检查,23名受试者(7名女性,16名男性,平均年龄(标准差)59.2(7.8)岁)被诊断为可能患有PD,16例患者(5名女性,11名男性,平均年龄72(7.6)岁,p<0.001)被诊断为可能患有PS。在PD组中,Hoehn和Yahr严重程度平均为2.7(1.1),疾病平均持续时间9.5(6.2)年,左旋多巴治疗平均持续时间(20例患者)6.7(5.5)年。在PS组中,Hoehn和Yahr的相应值分别为3.3(0.9),疾病平均持续时间6.2(4.1)年,左旋多巴治疗平均持续时间(10例患者)1.6(1.1)年。在隔夜停用所有其他多巴胺能药物后,皮下注射单剂量盐酸阿扑吗啡溶液,相当于每千克体重0.05毫克。在测试前每天给予多潘立酮60毫克,以避免APO产生不良外周效应。在给予APO 20分钟后,我们注意到临床有明显改善,即在23例PD患者中的19例和16例PS患者中的1例中,哥伦比亚大学评定量表(CURS)上治疗前运动评分值至少降低了30%。在PD组中,APO给药前CURS平均值为30.7(19.5),给药后为14.7(10.3),差异非常显著(p<0.001)。在PS组中,仅发现治疗后CURS略有下降,APO给药前为39.8(17.5),给药后为37.8(17.5)(p<0.05)。
在个体患者中,这些结果大多证实了对PD或PS的推测诊断。即使在PD组中最严重的病例中,测试也表明纹状体中多巴胺受体的功能仍然保留。因此,阿扑吗啡试验似乎是PD和PS鉴别诊断的有用工具。